GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cytek Biosciences Inc (NAS:CTKB) » Definitions » PB Ratio

CTKB (Cytek Biosciences) PB Ratio : 1.21 (As of Apr. 05, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Cytek Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-05), Cytek Biosciences's share price is $3.71. Cytek Biosciences's Book Value per Share for the quarter that ended in Dec. 2024 was $3.06. Hence, Cytek Biosciences's PB Ratio of today is 1.21.

Good Sign:

Cytek Biosciences Inc stock PB Ratio (=1.2) is close to 5-year low of 1.2.

The historical rank and industry rank for Cytek Biosciences's PB Ratio or its related term are showing as below:

CTKB' s PB Ratio Range Over the Past 10 Years
Min: 1.2   Med: 2.87   Max: 8.2
Current: 1.21

During the past 6 years, Cytek Biosciences's highest PB Ratio was 8.20. The lowest was 1.20. And the median was 2.87.

CTKB's PB Ratio is ranked better than
72.41% of 790 companies
in the Medical Devices & Instruments industry
Industry Median: 2.15 vs CTKB: 1.21

During the past 12 months, Cytek Biosciences's average Book Value Per Share Growth Rate was 1.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 0.40% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Cytek Biosciences was 0.40% per year. The lowest was 0.40% per year. And the median was 0.40% per year.

Back to Basics: PB Ratio


Cytek Biosciences PB Ratio Historical Data

The historical data trend for Cytek Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytek Biosciences PB Ratio Chart

Cytek Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial - 5.39 3.25 3.03 2.12

Cytek Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.24 1.89 1.87 2.12

Competitive Comparison of Cytek Biosciences's PB Ratio

For the Medical Devices subindustry, Cytek Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytek Biosciences's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytek Biosciences's PB Ratio falls into.


;
;

Cytek Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cytek Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=3.71/3.063
=1.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cytek Biosciences  (NAS:CTKB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cytek Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Cytek Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytek Biosciences Business Description

Traded in Other Exchanges
N/A
Address
47215 Lakeview Boulevard, Fremont, CA, USA, 94538
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Executives
Ming Yan director, officer: Chief Technology Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Patrick Jeanmonod officer: Chief Financial Officer C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Wenbin Jiang director, officer: President and CEO C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Philippe Busque officer: SVP, Global Sales and Services 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Jack Ball director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Paul Christopher Williams officer: Chief Operating Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Don M Hardison director
Deborah J Neff director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BLVD., FREMONT CA 94538
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Vera Imper director C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
Theresa Cameron director C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Feng Deng director SUITE 1701, 17/F HUTCHISON HOUSE, 10 HARCOURT ROAD, CENTRAL, HONG KONG K3 00000
Ra Capital Nexus Fund Ii, L.p. director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116